Cyclacel pharmaceuticals announces closing of exercise of warrants for $2.1 million gross proceeds

Berkeley heights, n.j., nov. 14, 2024 (globe newswire) -- cyclacel pharmaceuticals, inc. (nasdaq: cycc, nasdaq: cyccp; "cyclacel" or the "company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it closed its previously announced transaction involving the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in may 2024, at a reduced exercise price of $0.415 per share. the resale of the shares of common stock issued upon exercise of the existing warrants is registered pursuant to an effective registration statement on form s-1 (file no. 333-279157).
CYCC Ratings Summary
CYCC Quant Ranking